瑞士納沙泰爾–(BUSINESS WIRE)–(美國商業資訊) — Swiss Advanced Vision (SAV-IOL)宣布上市Harmonis上市，這是一種用於白內障手術的可客製人工水晶體(IOL)，具有先進的延伸景深(EDOF)光學技術。眼科醫師有史以來第一次能夠在手術之前用一個Web介面的配置器將人工水晶體的各項光學參數調校至最佳水準，以適配所期望的視力結果。SAV-IOL將在9月21-25日於維也納召開的歐洲白內障和屈光外科醫師協會(ESCRS)第36屆年會期間向市場發布Harmonis。 為了使眼外科醫師及其患者獲得最佳視力，Harmonis Web介面的配置器可針對近距、中距和遠距視力的光分布比率、閱讀距離(Add)和 延伸景深(EDOF)提供一套可選擇的參數，形成合計超過3,000種的光學配置。 Harmonis與SAV-IOL現有的Eden和Lucidis人工水晶體產品陣容一起，向眼外科醫師提供了一系列用於白內障手術的優質、平價、精良、如今可客製的EDOF水晶體。所有三款產品的製造均採用公司獲得專利的瞬間聚焦光學技術，旨在延伸人工水晶體的景深，向患者提
Author: Business Wire
Swiss Advanced Visionが初のカスタマイズ可能な白内障手術用EDOF IOLとなるHarmonisを発表
スイス・ヌーシャテル–(BUSINESS WIRE)–（ビジネスワイヤ） — Swiss Advanced Vision（SAV-IOL）は、白内障手術用に、先進的な焦点深度拡張型（EDOF）光学技術を備え、カスタマイズ可能な眼内レンズ（IOL）であるHarmonisの投入を発表しました。眼科医は初めて、手術に先立ち、ウェブ型コンフィギュレーターを使用して、望ましい視力が得られるよう、レンズの最適な光学パラメーターを決定できるようになります。SAV-IOLはHarmonisを、9月21～25日にウィーンで開催される第36回欧州白内障・屈折手術学会（ESCRS）で市場向けに紹介します。 Harmonisのウェブ型コンフィギュレーターは、眼科外科医とその患者が最適な視力を達成できるよう、近見／中間／遠見視力の配光比率、近用・遠用（加入度数）、焦点深度拡張（EDOF）に関する一連の選択可能なパラメーターを提供することで、3000種超の光学設定を実現します。 HarmonisがSAV-IOLの既存のIOLポートフォリオであるEdenおよびLucidisに加わったことで、高品質／廉価／高
Swiss Advanced Vision上市Harmonis – 首款用于白内障手术的可定制EDOF人工晶体
瑞士纳沙泰尔–(BUSINESS WIRE)–(美国商业资讯) — Swiss Advanced Vision (SAV-IOL)宣布上市Harmonis，这是一种用于白内障手术的可定制人工晶体(IOL)，具有先进的扩展聚焦深度(EDOF)光学技术。眼科医师有史以来第一次能够在手术之前用一个基于Web的配置器将人工晶体的各项光学参数调校至最佳水平，以适配所期望的视力结果。SAV-IOL将在9月21-25日于维也纳召开的欧洲白内障和屈光外科医师协会(ESCRS)第36届年会期间向市场发布Harmonis。 为了使眼外科医师及其患者获得最佳视力，Harmonis基于Web的配置器可针对近距、中距和远距视力的光分布比率、阅读距离(Add)和扩展聚焦深度(EDOF)提供一套可选择的参数，形成合计超过3,000种的光学配置。 Harmonis与SAV-IOL现有的Eden和Lucidis人工晶体产品阵容一起，向眼外科医师提供了一系列用于白内障手术的优质、平价、精良、如今可定制的EDOF晶体。所有三款产品的制造均采用公司获得专利的瞬间聚焦光学技术，旨在扩展人工晶体的聚焦深度，向患者提供优质
Swiss Advanced Vision lança a Harmonis – a primeira IOL personalizável com EDOF para cirurgias de catarata
NEUCHATEL, Suíça–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) anunciou o lançamento da Harmonis, uma lente intraocular (IOL) personalizável com tecnologia óptica avançada de profundidade focal estendida (EDOF) para cirurgias de catarata. Pela primeira vez, os oftalmologistas estarão aptos a utilizar o configurador com base na Web para definir os melhores parâmetros ópticos das lentes para que se ajustem ao resultado visual desejado, antes da cirurgia. A SAV-IOL vai apresentar a Harmonis no
Riassunto: Swiss Advanced Vision lancia Harmonis, la prima lente intraoculare EDOF personalizzabile per la chirurgia della cataratta
NEUCHATEL, Svizzera–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) ha annunciato il lancio di Harmonis, una lente intraoculare (IOL) personalizzabile basata sull’avanzata tecnologia ottica EDOF (Extended Depth Of Focus) per la chirurgia della catara…
Swiss Advanced Vision lanza Harmonis, el primer lente intraocular personalizable de profundidad de foco extendida para cirugía de cataratas
NEUCHATEL (Suiza)–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) ha anunciado el lanzamiento de Harmonis, una tecnología óptica de lente intraocular personalizable con profundidad de foco extendida avanzada para cirugía de cataratas. Por primera vez en la historia, los oftalmólogos podrán utilizar un configurador basado en la web para definir los mejores parámetros ópticos del lente a prescribir con el resultado visual deseado antes de la cirugía. SAV-IOL lanzará Harmonis al mercado durante
Samenvatting: Swiss Advanced Vision lanceert Harmonis – De eerste aanpasbare EDOF IOL voor cataractchirurgie
NEUCHATEL, Switzerland–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) heeft de lancering aangekondigd van Harmonis, een aanpasbare intraoculaire lens (IOL) met geavanceerde EDOF (extended depth of focus) optische technologie voor cataractchirurgie. Voor het eerst zullen oogartsen een webgebaseerde configurator kunnen gebruiken om de beste optische parameters van de lens te definiëren die passen bij het gewenste visuele resultaat voorafgaand aan de operatie. SAV-IOL zal Harmonis op de markt b
Swiss Advanced Vision lance Harmonis, la première lentille intraoculaire à profondeur de champ étendue personnalisable
NEUCHÂTEL, Suisse–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) vient d’annoncer le lancement d’Harmonis, une lentille intraoculaire personnalisable équipée d’une technologie optique avancée à profondeur de champ étendue pour l’opération de la cataracte. Pour la toute première fois, les ophtalmologues seront en mesure d’utiliser un configurateur en ligne pour définir les paramètres optiques optimaux de la lentille en accord avec le résultat visuel escompté avant l’intervention chirurgicale.
Swiss Advanced Vision präsentiert Harmonis – die erste anpassbare EDOF-Intraokularlinse für die Kataraktchirurgie
NEUCHATEL, Schweiz–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) meldet die Einführung von Harmonis, einer anpassbaren Intraokularlinse (IOL) für die Kataraktchirurgie, die mit der hochmodernen optischen EDOF (Extended Depth of Focus)-Technologie ausgestattet ist. Damit haben Ophthalmologen zum ersten Mal die Möglichkeit, vor der Operation die optischen Parameter der Linse mithilfe eines webbasierten Konfigurators so festzulegen, dass sie dem angestrebten Sehergebnis am besten entsprechen.
Swiss Advanced Vision Launches Harmonis – The First Customizable EDOF IOL for Cataract Surgery
NEUCHATEL, Switzerland–(BUSINESS WIRE)–Swiss Advanced Vision launches Harmonis, the first customizable intraocular lens with advanced EDOF technology for cataract surgery.
Gary Winer Joins LENSAR, Inc. Board of Directors
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. announces global healthcare senior executive Gary Winer has joined the company’s board of directors.
Global Glass Lens Market 2018-2022| Progressive Glass Lenses Segment Dominates the Global Market| Technavio
LONDON–(BUSINESS WIRE)–#Research–According to the latest market research report by Technavio, the global glass lens market is expected to accelerate at a CAGR of around 4% until 2022.
Mati Therapeutics Interim Phase II Nepafenac Clinical Trial Results Signal Significant Post-op Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that it has completed a planned interim analysis of an ongoing Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular drug delivery platform. The trial is a multi-center, randomized, masked evaluation of nepafenac vs. placebo in 75 patients undergoing cataract surgery. The primary endpoint is to evaluate pain and the secondary endpoint is to evalua
Second Sight Appoints Pat Ryan Chief Operating Officer
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume responsibility for Research & Development, Manufacturing, Planning & Ma
2020 On-site appoints Alexis McLaughlin as Chief Executive Officer, Closes Over $5MM in Series B Financing and Named to the Inc. 5000
BOSTON–(BUSINESS WIRE)–#HR–2020 On-site (2020), America’s leading provider of on-site vision care for businesses and schools, serving over 450 leading employers, announced this morning the appointment of Alexis McLaughlin as 2020’s new Chief Executive Officer. McLaughlin will also join 2020’s Board of Directors. Most recently, McLaughlin was SVP/General Manager of Retail Licensed Brands at Luxottica Retail, where she was responsible for $500MM in revenue across 1,000 stores in North America. In h
Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). The study (NCT03298867 and EudraCT 2017-002763-18) enrolled 83 patients at 13 sites across the United States, Germany and Italy. Topline results are expected in the second quarter of 2019. “Our success in rapidly enrolling this trial speaks to the significant unmet ne
Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences has boosted its finance team with two key appointments, Chief Financial Officer Julie Feder and VP of Finance Kylie Reynolds.
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously announced transaction with Juvenescence Limited, a global l…
PolyActiva Commences Its First Phase I Clinical Trial with Potential to Improve Daily Lives of Millions of Glaucoma Patients
MELBOURNE, Australia–(BUSINESS WIRE)–Revolutionary new glaucoma treatment, which could remove need for eye drop use, enters clinical trials with USD$12m venture capital-backing.
NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 2:35 p.m. Eastern time (5:35 p.m. Pacific time). The conference is being held at the St. Regis New York in New York City. A live webc